Navigation Links
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Date:12/10/2009

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's ability to think clearly, relate to others, and distinguish between reality and imagination. In the U.S., approximately 2.4 million Americans have schizophrenia, with men and women affected equally.(1) Non-adherence to medication treatment is a common problem encountered in patients with schizophrenia, which can lead to relapse (an increase in symptoms) and hospitalization.(2) Since both INVEGA SUSTENNA and RISPERDAL CONSTA are given by a healthcare professional, it offers the physician a way to monitor patient medication adherence and intervene when a patient misses a dose. Both products offer flexibility to physicians and patients, based on their dosing regimens, thereby offering an important option to those who may need it.

The objective of this study was to show that INVEGA SUSTENNA was statistically similar (non-inferior) to RISPERDAL CONSTA, as measured by the Positive and Negative Syndrome Scale (PANSS). INVEGA SUSTENNA, a once-monthly injectable atypical antipsychotic, was recently approved in the U.S. for the acute and maintenance treatment of schizophrenia in adults. RISPERDAL CONSTA, the first long-acting injectable atypical antipsychotic, was approved for the treatment of schizophrenia in adults in the U.S. in 2003, and recently was approved for use as maintenance therapy in the treatment of Bipolar I Disorder.

"Physicians need treatment options that match the needs of their patients, particularly when compliance is a significant issue. INVEGA SUSTENN
'/>"/>

SOURCE Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and PITTSBURGH , Aug. ... ) today announced that its shareholders have approved ... PRGO ; TASE) and the related issuance ... an extraordinary general meeting of shareholders held today. ... cast at the extraordinary general meeting. In addition, ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
(Date:8/27/2015)... 27, 2015 DURECT Corporation (Nasdaq: DRRX ... at three upcoming healthcare conferences.  , ... present at the Rodman & Renshaw Investment Conference on ... conference is being held at the St. Regis Hotel ... live audio webcast of the presentation will be available ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2
...  Digestive Care, Inc. (DCI), announced that the company ... approval of its New Drug Application (NDA) for ... Insufficiency (EPI) due to cystic fibrosis (CF) or ... unique pancreatic enzyme product containing bicarbonate-buffered enteric-coated microspheres ...
... May 18, 2012  Ocera Therapeutics Inc., a privately-held ... of proprietary agents to treat gastrointestinal and liver ... CE Mark for Zysa™ (spherical carbon adsorbent, formerly ... (IBS-d), a condition affecting 10-15% of the Western ...
Cached Medicine Technology:Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 3
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor ... Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an official ... , “With the help of the medical community and the University of Illinois at ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones ... personally be struggling with chemical dependency, may be able to find some hope ... results-driven holistic treatment center for addiction located in Western Michigan. Focusing on several ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... “ Frequentz ... look at the latest and coolest applications on the market for iOS, Android, and ... and shared with viewers how this software allows businesses to track product movement from ...
(Date:8/28/2015)... FL. (PRWEB) , ... August 28, 2015 , ... ... for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on ... that it should begin with the employer and employees getting together for meaningful ...
(Date:8/28/2015)... TN (PRWEB) , ... August 28, 2015 , ... ... recipients of the Veterans Award, honoring military veterans leading in business. Mr. ... honorees. , The inaugural Nashville Business Journal's 2015 Veterans Awards will ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2
... US researchers have discovered a non-invasive elastography technique that ... to radiation. ,The technique found by ... measuring muscle noise to reveal a patients condition. ... 16 sensors, each 1.5 centimetres apart, along the thigh ...
... Huxley has said that, "Although there was support for a ... of heart disease , the relationship is not as strong ... may have on heart disease are dwarfed by other risk ... ,Coronary heart disease is the leading cause ...
... who are hard of hearing. But the authorities have hardly ... problem has mysteriously persisted for decades in the Muslim-dominated Jhumarvad ... ,Shamshool Mia, a 62-year-old villager, said: "I am hard ... treatment failed to cure me. I will have to suffer ...
... public support for the fight against kidney diseases was kicked ... from the marathon, hosted by the New York Road Runners ... Arab Emirates (UAE), will go to the US National Kidney ... entrants from around the world, including 1000 women, 29 runners ...
... suspects in police custody is standard operating procedure for ... the idea that using a Taser could lead to ... the final results of a study conducted by emergency ... (UCSD) Medical Center showed no lasting effects of the ...
... Even before women with breast cancer undergo chemotherapy, ... activity levels, according to a new study ... in Omaha, Nebraska. ,Researchers say their ... following breast cancer surgery and before any further ...
Cached Medicine News:Health News:The Plight of Jharkhand's Mysterious deaf Village 2Health News:Healthy Humans Not Harmed By Taser 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 3
... new Eclipse TS-100 is an innovative ... high quality tool complements any research ... CFI60 optics offer brilliant, sharp ... superb optical performance with high resolution ...
... Nikon Instruments Inc., a world leader ... the introduction of its new Universal ... Nikon Eclipse upright microscope models, including ... This Universal Epi Illuminator provides ...
... monochrome digital CCD camera ideal for demanding low-light ... high-resolution images with outstanding clarity and detail. ... Live Image Frame Rate - ... 170x120 (8x8) Image Display Speed ...
... Sonys new DFW-SX910 digital camera is ... CCD with square pixels and offers excellent ... resolution). This camera delivers uncompressed, ... easy-to-use asynchronous electronic shutter function with an ...
Medicine Products: